Skip to main content
Equibles
ACTU logo

ACTU · Actuate Therapeutics, Inc. · Metrics

Track ACTU — free

Use ACTU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACTU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.07 -0.08 (-6.96%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$25.70M
Shares
24.01M

ACTU metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.07
Market cap
$25.70M

Price action

20 metrics
Price change (1W)
-27.7%
Price change (30D)
+5.9%
Price change (3M)
-47.0%
Price change (6M)
-58.2%
Price change (YTD)
-82.5%
Price change (1Y)
-84.6%
Trailing year
Price change (5Y)
—
52-week high
$8.09
52-week low
$0.97
Change from 52-week high
-86.8%
Change from 52-week low
+10.3%
Annualized volatility
102.7%
Annualized volatility (3M)
131.1%
Beta
1.8
RSI (14D)
40.1
Price vs SMA 50
-17.1%
Price vs SMA 200
-66.7%
Avg volume (3M)
382,877
Relative volume
0.6
Average dollar volume
$579,225

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
24.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
26.0
reciprocal yield 3.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-79.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$20.77M
Net income (TTM)
−$20.45M
Trailing 12 months
Diluted EPS (TTM)
$-0.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.34

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-2,067.8%
Return on assets
-393.4%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.2
Interest coverage
-1,025.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.43M
Latest balance sheet
Cash & equivalents
$4.43M
Total assets
$5.20M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.84M
Capital expenditures (TTM)
—
R&D (TTM)
$8.94M
SG&A (TTM)
—
Stock compensation (TTM)
$6.04M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
63
13F filer change QoQ
+2
Institutional ownership
56.3%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1652935 CUSIP 005083100 13F (30d) 17 filings 17 filers Visit website